Veterinary Medicines

Zeronil Combo 67 mg/60.3 mg Spot-on Solution for Small Dogs

Not authorised
  • (S)-Methoprene
  • Fipronil
Download as PDF

Product identification

Medicine name:
Zeronil Combo 67 mg/60.3 mg Spot-on Solution for Small Dogs
Fleatix Comp vet 67 mg/60,3 mg Spot-on, lösning
Active substance:
  • (S)-Methoprene
  • Fipronil
Target species:
  • Dog
Route of administration:
  • Spot-on use

Product details

Active substance and strength:
  • (S)-Methoprene
    60.30
    milligram(s)
    /
    1.00
    Pipette
  • Fipronil
    67.00
    milligram(s)
    /
    1.00
    Pipette
Pharmaceutical form:
  • Spot-on solution
Withdrawal period by route of administration:
  • Spot-on use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53AX65
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Sweden
Package description:
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 160 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 150 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 90 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 60 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 30 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 24 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 21 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 20 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 18 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 15 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 12 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 10 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 9 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 8 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 6 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 4 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 3 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 2 pipettes in individual foil sachets.
  • A white pipette composed of a heat-formed shell of polypropylene/cyclic olefin copolymer/polypropylene layer and polyethylene/ethylene vinyl alcohol/polyethylene layer. Box with 1 pipette in an individual foil sachet.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Chanelle Pharmaceuticals Manufacturing Limited
Marketing authorisation date:
Manufacturing sites for batch release:
  • Chanelle Pharmaceuticals Manufacturing Limited
Responsible authority:
  • Swedish Medical Products Agency
Authorisation number:
  • 56151
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0386/002

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download
Swedish (PDF)
Published on: 2/05/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."